Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1

NF1 is a debilitating rare genetic disorder that causes tumours to form along nerves, often manifesting in childhood. It affects approximately one in 2,500 individuals worldwide and can lead to severe complications, including pain, disfigurement, and malignancies. Despite its impact, treatment options remain limited, with many patients facing invasive surgeries or therapies with severe side … Continued The post Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1 appeared first on Healx .